Anand Gopal, MD
Retina Specialist · Des Plaines, ILNPI 1720571722
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 37 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 18 manufacturers, the largest accounting for just 20.5% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2022 at $929 and has fallen 63.9% since, to $335 in 2025. That places this record below the midpoint for retina specialist clinicians in IL, where the typical reported total is $2,402.
Across 37 payments — averaging $64.91 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Alcon$492
- Bausch & Lomb Americas Inc.$413
- Apellis Pharmaceuticals, Inc.$284
- Regeneron Healthcare Solutions, Inc.$205
- Genentech, Inc.$194
- Sight Sciences, Inc.$128
- plus $688 from 12 others
What the payments were for
- Food & beverage$2,402100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Alcon | 4 | $492 |
| Bausch & Lomb Americas Inc. | 4 | $413 |
| Apellis Pharmaceuticals, Inc. | 8 | $284 |
| Regeneron Healthcare Solutions, Inc. | 3 | $205 |
| Genentech, Inc. | 3 | $194 |
| Sight Sciences, Inc. | 1 | $128 |
| Genentech USA, Inc. | 1 | $122 |
| Johnson & Johnson Surgical Vision, Inc. | 1 | $118 |
| Biogen | 2 | $96 |
| Alimera Sciences, Inc. | 2 | $81 |
| Glaukos Corporation | 1 | $77 |
| Dutch Ophthalmic, USA | 1 | $70 |
| Oyster Point Pharma, Inc. | 1 | $33 |
| Carl Zeiss Meditec USA, Inc. | 1 | $20 |
| AbbVie | 1 | $20 |
| Astellas Pharma US Inc | 1 | $19 |
| Stryker | 1 | $16 |
| Eyepoint US, Inc. | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Clareon$406
- STELLARIS$362
- EYLEA HD$128
- OMNI(R) SURGICAL SYSTEM (US)$128
- VABYSMO$122
- Tecnis IOL$118
- Syfovre$102
How this compares
$2,402 in reported general payments places this provider in the 50th percentile of 70 retina specialist providers in Illinois.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Prednisolone Acetate | 114 | $5,305 |
| Polymyxin B Sul-TrimethoprimPolymyxin B Sulf/Trimethoprim | 105 | $775 |
Paid to pharmacies, not to this prescriber.
Other retina specialist in Des Plaines
- Bryan KimDes Plaines$8K
- Kyle BlairDes Plaines$5K
- Saira KhannaDes Plaines$5K
- George WyhinnyDes Plaines$2K
- Enrique Garcia-ValenzuelaDes Plaines$2K
- Daniel AlterDes Plaines$2K
- Michael BlairDes Plaines$927
- Robert GaroonDes Plaines$515
- Mathew MaccumberHarvey$219K
- Rahul KomatiChicago$143K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.